Ad
related to: overall success rate of chemotherapy infusion
Search results
Results from the WOW.Com Content Network
The goal is to extend progression survival and overall survival rates. Clinical trials have validated the effectiveness of this approach making it the standard of care for patients. Research by Attal et al has shown that patients with myeloma who undergo HDC experience significantly improved survival rates compared to those receiving ...
For resistant disease (chemotherapy-free interval of < 90 days) overall response rate (ORR) was 21.3% with 46.8% disease control rate and 5.1 months median overall survival (OS). [17] Lurbinectedin is also being investigated in combination with doxorubicin as second-line therapy in a randomized Phase III trial.
The 6-year leukemia-free survival (LFS) and overall survival (OS) rates were 84.4% and 89.5%, respectively, in the low-risk group, which were similar to the rates in the intermediate-risk group (59.2% and 65.2%, respectively); The 6-year LFS and OS were 76.4% and 82.1%, respectively, in patients who received a high dose of donor CD3+ T cells ...
Long-term effects were also a concern, as patients were often cured and could expect long survival after chemotherapy. Infertility was a major long-term side effect, and even more seriously, the risk of developing treatment-related myelodysplasia or acute leukemia was increased up to 14-fold in patients who received MOPP. [ 14 ]
A total of 359 participants were randomized 1:1 to receive a single infusion of axicabtagene ciloleucel following fludarabine and cyclophosphamide lymphodepleting chemotherapy or to receive second-line standard therapy, consisting of two or three cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in participants who ...
Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall survival. The drug that is administered is the same as the drug that achieved remission. [6]: 55–59
The overall response rate was 85% in VEN+G arm compared to 71% in GClb arm, p=0.0007. [9] The trial also demonstrated statistically significant improvements in rates of minimal residual disease negativity (less than one CLL cell per 10 4 leukocytes) in bone marrow and peripheral blood. [9] Overall survival data were not mature at this analysis. [9]
High-dose chemotherapy using the CMVP combination was found to be able to be given safely to younger patients with high-risk breast cancer. The high-dose chemotherapy resulted in a significantly low relapse rate, and high-dose chemotherapy was associated with significantly longer disease-free and overall survival in this patient population.
Ad
related to: overall success rate of chemotherapy infusion